3Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial[J]. Gene Ther,2001,8(4) :308-315.
4Tango Y, Fujiwara T, Itoshim T, et al. Adenovirus-mediated pl4ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells[J]. Hum Gene Ther, 2002, 13(11):1373-1382.
5Hecht JR, Bedford R, Abbmzzese JL, et al. A Phase I/Ⅱ Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma [J].Clin Cancer Res, 2003,9(2): 555-561.
6Wesseling JG, Yamamoto M, Adachi Y, et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma [J]. Cancer Gene Ther, 2001,8 (12): 990-996.
7Ohashi M, Kanai F, Tanaka T, et al. In vivo adenovirus-mediated prodrug gene therapy for carcinoernbryonic antigen-producing pancreatic cancer[J]. Jpn J Cancer Res, 1998,89 (4): 457-462.
8Miki K, Xu M, Gupta A, et al. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate [J]. Cancer Res,2001,61(18) :6805-6810.
9Calbo J, Marotta M, Caseallo M, et al. Adenovirus-mecdiated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer[J]. Cancer Gene Ther, 2001,8(10): 740-750.
10Hwang RF, Gordon EM,Anderson WF, et al. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene[J]. Surgery, 1998,124(2):143-150.
